Literature DB >> 30569509

A magic drug target: Androgen receptor.

Dan Li1, Wenfang Zhou1,2, Jinping Pang1, Qin Tang1, Bingling Zhong1, Chao Shen1, Li Xiao3, Tingjun Hou1,2.   

Abstract

Androgen receptor (AR) is closely associated with a group of hormone-related diseases including the cancers of prostate, breast, ovary, pancreas, etc and anabolic deficiencies such as muscle atrophy and osteoporosis. Depending on the specific type and stage of the diseases, AR ligands including not only antagonists but also agonists and modulators are considered as potential therapeutics, which makes AR an extremely interesting drug target. Here, we at first review the current understandings on the structural characteristics of AR, and then address why and how AR is investigated as a drug target for the relevant diseases and summarize the representative antagonists and agonists targeting five prospective small molecule binding sites at AR, including ligand-binding pocket, activation function-2 site, binding function-3 site, DNA-binding domain, and N-terminal domain, providing recent insights from a target and drug development view. Further comprehensive studies on AR and AR ligands would bring fruitful information and push the therapy of AR relevant diseases forward.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  anabolic deficiencies; androgen receptor; breast cancer; drug target; ovarian cancer; pancreatic cancer; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 30569509     DOI: 10.1002/med.21558

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  9 in total

1.  PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-05-18       Impact factor: 4.345

Review 2.  Monoubiquitination in Homeostasis and Cancer.

Authors:  Yujie Chen; Dandan Zhou; Yinan Yao; Yutong Sun; Fan Yao; Li Ma
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

3.  Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.

Authors:  Jin-Ping Pang; Chao Shen; Wen-Fang Zhou; Yun-Xia Wang; Lu-Hu Shan; Xin Chai; Ying Shao; Xue-Ping Hu; Feng Zhu; Dan-Yan Zhu; Li Xiao; Lei Xu; Xiao-Hong Xu; Dan Li; Ting-Jun Hou
Journal:  Acta Pharmacol Sin       Date:  2021-03-25       Impact factor: 7.169

4.  Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells.

Authors:  Manuel Abreu; Pablo Cabezas-Sainz; Thais Pereira-Veiga; Catalina Falo; Alicia Abalo; Idoia Morilla; Teresa Curiel; Juan Cueva; Carmela Rodríguez; Vanesa Varela-Pose; Ramón Lago-Lestón; Patricia Mondelo; Patricia Palacios; Gema Moreno-Bueno; Amparo Cano; Tomás García-Caballero; Miquel Ángel Pujana; Laura Sánchez-Piñón; Clotilde Costa; Rafael López; Laura Muinelo-Romay
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

5.  Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer.

Authors:  Xiaoli Li; Duanfang Zhou; Yongqing Cai; Xiaoping Yu; Xiangru Zheng; Bo Chen; Wenjun Li; Hongfang Zeng; Moustapha Hassan; Ying Zhao; Weiying Zhou
Journal:  NPJ Breast Cancer       Date:  2022-01-10

Review 6.  Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers.

Authors:  Sujun Wu; Kun Yu; Zhengxing Lian; Shoulong Deng
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

7.  MiR-942-3p as a Potential Prognostic Marker of Gastric Cancer Associated with AR and MAPK/ERK Signaling Pathway.

Authors:  Wenjia Liu; Nanjiao Ying; Xin Rao; Xiaodong Chen
Journal:  Curr Issues Mol Biol       Date:  2022-08-24       Impact factor: 2.976

8.  Systematic pan-cancer analysis on the expression and role of regulator of chromatin condensation 1/small nucleolar RNA host gene 3/small nucleolar RNA host gene 12.

Authors:  Kai Hu; Huomei Yu; Shiyan Liu; Deyu Liao; Yan Zhang
Journal:  Front Mol Biosci       Date:  2022-09-06

9.  AKR1C2 acts as a targetable oncogene in esophageal squamous cell carcinoma via activating PI3K/AKT signaling pathway.

Authors:  Zhan-Fei Zhang; Tie-Jun Huang; Xin-Ke Zhang; Yu-Jie Xie; Si-Ting Lin; Fei-Fei Luo; Dong-Fang Meng; Hao Hu; Jing Wang; Li-Xia Peng; Chao-Nan Qian; Chao Cheng; Bi-Jun Huang
Journal:  J Cell Mol Med       Date:  2020-07-17       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.